TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06307899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Corner Stretch
Description: Individuals will be positioned in a standing position with the elbow in 90° flexion and the shoulder in 90° abduction, placing the palm on a flat surface. For stretching, individuals will be asked to increase shoulder horizontal abduction by rotating the trunk anteriorly and contralaterally. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Stretching
Description: Individuals will be positioned supine with the shoulder in 90º abduction and external rotation and the elbow in 90º flexion. Stretching will be applied by the physiotherapist from just distal to the elbow in the direction of horizontal abduction of the shoulder. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Stretching
Description: Individuals will be in a sitting position with their hands clasped behind the head. The PM muscle will be stretched in the direction of horizontal abduction by placing the physiotherapist's hands anterior to the elbows. Passive stretching will be continued for 10 seconds, followed by 6 seconds of maximum voluntary isometric contraction of the PM muscle. The procedure will be repeated four times with 30 seconds of rest.
Study: NCT05907278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Cooking Education
Description: Participants attend the ACE Program for 12 weeks after school.~On one assigned day of the week, participants attend ACE virtually. The session will begin with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes).~On any day during the week, the students will make a dish using groceries they received (1 hour).
Study: NCT04924842

Intervention type: OTHER
Intervention: Review of medical file
Description: Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.

Intervention type: OTHER
Intervention: Phone call interview
Description: less than 15 minutes phone call
Study: NCT05687526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: 12-17 years old: Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.~5-11years old: Telitacicept 3.0-3.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.
Study: NCT05722574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Romantic Competence Intervention
Description: Online, 30-minute self-administered relationship competence program for youth ages 16-20

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only Control Condition
Description: Online, 30-minute self-administered relationship education activity for youth ages 16-20
Study: NCT06265870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albendazole
Description: Participants receive empiric anthelminthic treatment which is albendazole 400 mg twice a day for seven consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin or albendazole
Description: Participants will receive specific anthelminthic treatment tailored to the results of the stool tests
Study: NCT06610058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization first Control second
Description: Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control first Instrument Assisted Soft Tissue Mobilization second
Description: This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
Study: NCT06609317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital therapeutic motion-based device
Description: This intervention includes use of a digital therapeutic motion-based device for pelvic floor muscle training
Study: NCT06610071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG administration
Description: The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG administration
Description: The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG administration
Description: The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG administration
Description: The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
Study: NCT06610409

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: Blood sample for CXCL5 Level

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: Blood sample for CXCL5 Level
Study: NCT06609772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Pain Education
Description: Individualised Pain Education
Study: NCT04681599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filter
Description: Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filter
Description: Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scavenger face tent
Description: A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scavenger face tent
Description: A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria
Study: NCT05615493

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radial extracorporeal shock wave therapy
Description: Radial extracorporeal shock wave therapy (r ESWT) will be applied by Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with a focusing depth of 4cm.The intensity will be 0.10 mJ to 0.3mJ/mm2 (2.5 bar), with frequency 4 Hz every week for one month .No anesthetic or analgesic drugs will be administered to patients during the therapy session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham radial extracorporeal shock wave therapy
Description: Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) used under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with intensity of 0.10 mJ to 0.3mJ/mm2 (2.5 bar), \& frequency 4 Hz every week for one month without operating the machine .
Study: NCT05919862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot system
Description: Prosthetically guided Implant placement utilising robotic surgery based on a digital plan

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Freehand surgery
Description: Freehand implant placement by experienced surgeon.
Study: NCT04871854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: patients treated with Tocilizumab for Covid-19 infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional Covid -19 therapy
Description: patients treated with traditional therapy for Covid-19 infection
Study: NCT05856721

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: stool analysis
Description: Detection of prevalence and pattern of intestinal parasitic infection in cirrhotic patients and the difference between cirrhotic patients and non-cirrhotic patients with no comorbidity.~To determine the most common risk factors of intestinal parasitic infection in cirrhotic patients.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: stool analysis
Description: Detection of prevalence and pattern of intestinal parasitic infection in cirrhotic patients and the difference between cirrhotic patients and non-cirrhotic patients with no comorbidity.~To determine the most common risk factors of intestinal parasitic infection in cirrhotic patients.
Study: NCT05203614

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Household Contribution
Description: Questionnaires

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Outside Contribution
Description: Questionnaires

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Questionnaires
Study: NCT05700669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AsiDNA
Description: All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AsiDNA
Description: All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AsiDNA
Description: All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AsiDNA
Description: All patients will receive a loading dose of AsiDNA intravenously (D1, D2, D3) followed by weekly intravenous administrations in combination with Olaparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is given orally in combination with AsiDNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is given orally in combination with AsiDNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is given orally in combination with AsiDNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is given orally in combination with AsiDNA
Study: NCT05804838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness stress reduction program group
Description: Conscious Awareness Based Stress Reduction program will be applied to women in this group, which will last for 8 weeks. Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Psychological Well-Being Scale, Beck Depression Scale, Prenatal Attachment Scale and Conscious Awareness Scale will be administered to the pregnant women who make up the intervention group before the implementation of the Mindfulness-Based Stress Reduction program. The intervention group will receive 1 session per week. Each session will last 80 minutes. After completing the 8-week MBSR program, data collection forms will be re-applied to the pregnant women in the intervention group and posttest-1 measurements will be made. After the posttest-1 measurements, the pregnants in the intervention group will be given posttest-2 measurements of the pregnants in the intervention group, 1 month after the measurements.
Study: NCT05178810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAB122
Description: Daily dose 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose
Study: NCT05109325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntERact
Description: The IntERact intervention includes: (1) three remotely delivered Health Coach therapist sessions that integrate behavioral therapy (motivational interviewing \[MI\] + cognitive behavioral therapy \[CBT\] and strengths-based care management (CM); as well as, (2) an APP supporting and enhancing the therapist intervention by: (a) conducting automated daily assessments; (b) delivering daily MI/CBT messages tailored by the daily surveys; (c) delivering GPS-enabled alert notifications and immediate one-touch pro-social support; (d) providing access to reminders regarding goals/strengths from the ED session, CBT tools/skills (e.g., infographics, coping strategies, harm reduction strategies), and other psychoeducation (e.g., safe storage); (e) facilitating one-touch contact with pro-social support, including the health coach and others; (f) providing easy linkage to care management resources (web links, phone numbers, contact information).
Study: NCT05764564

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Positive or negative pressure
Description: Positive or negative pressure is applied via a closed chamber.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positive or negative pressure
Description: Positive or negative pressure is applied via a closed chamber.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positive or negative pressure
Description: Positive or negative pressure is applied via a closed chamber.
Study: NCT06184516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reproductive organ sparing radical cystectomy
Description: Participants on this arm will undergo a reproductive organ sparing radical cystectomy if they are classified as favorable based on the decision tool.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical cystectomy
Description: Participants on this arm will undergo a radical cystectomy if they are classified as unfavorable based on the decision tool.
Study: NCT06005194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: InMotion
Description: A manualized physical activity counseling program that is based on the Diabetes Prevention Program (DPP) that has been adapted for TBI

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: InMotion
Description: A manualized physical activity counseling program that is based on the Diabetes Prevention Program (DPP) that has been adapted for TBI
Study: NCT06103500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis
Description: A clinical decision support algorithm for empiric antibiotic selection in suspected infection.
Study: NCT06119282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhaler
Description: Experimental: After the cesarean section, at the 8th hour postpartum, the VAS/GCA is evaluated, 4 drops of carrier oil are dropped on the upper and lower parts of the wick of the aroma stick, and then 15-20 drops of the prepared essential mixture are dropped and the woman is explained about its use. By the 8th hour of the postop, 4\*1 women are allowed to sniff. Before the application, the 30th and 60th minutes VAS/GOC, vital parameters are evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control Group Pregnant women included in the control group will be left to clinical care, and pain and vital parameters will be monitored starting from the 8th postoperative hour. The scales applied to the experimental groups will be applied on the 2nd postoperative day. Women in the control group who completed the study will be informed about the postpartum use of aromatherapy. Women who want aromatherapy application will be directed to GETAT center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Experimental: Test Massage When the studies conducted with the massage method are examined, back massage is applied for 10-30 minutes. Considering the working conditions of the institution, it is thought that a 10-minute massage may be sufficient for the application. The massage application is started at the postpartum 8th hour and applied for 10 minutes on the postoperative 0th day 1\*1, 2 times on the postoperative 1st and 2nd days when the woman feels ready. 30 and 60 minutes before application. then VAS/GCS, vital parameters are monitored.
Study: NCT04882735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acoramidis
Description: TTR stabilizer administered orally twice daily (BID)
Study: NCT05943964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual exercise and rehabilitation program
Description: Participants will have two 30-minute sessions per week for 12 weeks. The program will focus on aerobic exercises and stretching exercises. When applicable, stretching exercises will focus on areas of contractures, and joints with limited range of motion (ROM).~Sessions will be completed by a team of Physical Therapists using the established telemedicine platform at Children's Healthcare of Atlanta, as used routinely in the blood and marrow transplant clinic for clinical care (Epic). Adherence to the program will be encouraged during monthly standard clinic visits.
Study: NCT05552664

Intervention type: GENETIC
Group type: OTHER
Intervention: GIFT
Description: GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.

Intervention type: GENETIC
Group type: OTHER
Intervention: GIFT
Description: GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.

Intervention type: GENETIC
Group type: OTHER
Intervention: GIFT
Description: GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.

Intervention type: GENETIC
Group type: OTHER
Intervention: GIFT
Description: GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing.
Study: NCT05934786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive rehabilitation
Description: Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive rehabilitation
Description: Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.
Study: NCT05710718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureWick™ System
Description: The PureWick™ FEC is intended for non-invasive urine output management in female patients. The PureWick™ FEC is a flexible, contoured external catheter that is positioned against the area where urine exits the female body. The PureWick™ FEC will be connected to the PureWick™ Urine Collection System (PUCS) via connector tubing. The PUCS uses suction (not felt by the user) to pull voided urine through the device, regardless of the urine flow rate. Urine continues through vinyl tubing until it reaches a collection canister, away from the body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hollister® Female Urinary Pouch External Collection Device
Description: It is designed to be emptied and should be attached to a drainage bag. The FUP is made with hydrocolloid skin adhesive and polymer/copolymer plastics.
Study: NCT04853173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assess pain management modalities in adult outpatient tonsillectomy surgery
Description: use a post-operative analgesia protocol suitable for outpatient surgery. Namely a protocol of analgesia based on the taking of drugs per bone (by mouth) and not intravenous. Pain evaluation.
Study: NCT05991414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitor
Description: Participants provided home blood pressure monitor and instructions on use from pharmacist. They will measure home BP every 4-weeks for 7 days as per Hypertension Canada 7-day home BP protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced community pharmacist care
Description: Pharmacist to follow up with participants every month to review home BP readings. Then the pharmacist will send home BP readings and recommendations for changes to antihypertensive medication regimen to participants prescribing clinician. Pharmacist will then advise participants to follow up with their prescribing clinician.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual pharmacist care
Description: Participants will come into the pharmacist at baseline, 12- and 24-weeks to have their BP taken by the pharmacist. Pharmacist will provide education and counseling. Pharmacist will send BP readings to participants prescribing clinician with no recommendations for changes to antihypertensive therapy. After 6-months participants will be offered a home BP monitor and instructions on use.
Study: NCT04435704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous Oxytocin
Study: NCT06306105

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine Collagen Peptides
Description: consume 1 bottle per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo drink
Description: consume 1 bottle per day